Atopic Dermatitis

Atopic dermatitis severity is associated with learning disabilities in children, according to a study.

The FDA has extended the priority review period for abrocitinib’s New Drug Application for the treatment of moderate to severe atopic dermatitis, Pfizer announced in a press release.

Both 100 mg and 200 mg doses of once-daily abrocitinib improved signs and symptoms in patients with moderate to severe atopic dermatitis, according to a study.

Children with atopic dermatitis were more likely to experience a broad array of comorbidities than matched controls, from mental health conditions such as anxiety to dermatologic complications such as vitiligo, according to a study.

Patients with moderate to severe atopic dermatitis experienced statistically significant improvement with baricitinib 2 mg, according to a phase 3 study.

Chronic school and work absenteeism is more common in children with atopic dermatitis and their caregivers than in those with psoriasis, according to a study.

Abrocitinib combined with a medicated topical therapy was effective, well tolerated and improved quality of life in adolescents with atopic dermatitis, according to phase 3 results from the JADE TEEN Study.

Ruxolitinib demonstrated efficacy and a dual mode of action among patients with atopic dermatitis, according to a poster at South Beach Symposium Medical Dermatology Summit.

Kyowa Kirin reported positive phase 2 study results for KHK4083 in treating atopic dermatitis compared with placebo, according to a press release.

A new drug application under priority review for ruxolitinib cream for the treatment of atopic dermatitis has been accepted by the FDA, Incyte announced in a press release.